Pont C, Ginex T, Grinan-Ferre C, Scheiner M, Mattellone A, Martinez N, Arce EM, Soriano-Fernandez Y, Naldi M, De Simone A, Barenys M, Gomez-Catalan J, Perez B, Sabate R, Andrisano V, Loza MI, Brea J, Bartolini M, Bolognesi ML, Decker M, Pallas M, Luque FJ, Munoz-Torrero D (2021) <br />From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects<br /><i>Eur Journal of Medicinal Chemistry</i> <b>225</b>: 113779<br /><br />Lushchekina SV, Inidjel G, Martinez N, Masson P, Trovaslet-Leroy M, Nachon F, Koza MM, Seydel T, Peters J (2020) <br />Impact of Sucrose as Osmolyte on Molecular Dynamics of Mouse Acetylcholinesterase<br /><i>Biomolecules</i> <b>10</b>: <br /><br />Andersson CD, Martinez N, Zeller D, Allgardsson A, Koza MM, Frick B, Ekstrom F, Peters J, Linusson A (2018) <br />Influence of Enantiomeric Inhibitors on the Dynamics of Acetylcholinesterase Measured by Elastic Incoherent Neutron Scattering<br /><i>J Phys Chem B</i> <b>122</b>: 8516<br /><br />Peters J, Martinez N, Trovaslet M, Scannapieco K, Koza MM, Masson P, Nachon F (2016) <br />Dynamics of human acetylcholinesterase bound to non-covalent and covalent inhibitors shedding light on changes to the water network structure<br /><i>Phys Chem Chem Phys</i> <b>18</b>: 12992<br /><br />Marion J, Trovaslet M, Martinez N, Masson P, Schweins R, Nachon F, Trapp M, Peters J (2015) <br />Pressure-induced molten globule state of human acetylcholinesterase: structural and dynamical changes monitored by neutron scattering<br /><i>Phys Chem Chem Phys</i> <b>17</b>: 3157<br /><br />Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, Munoz M, Carrasco E, Caballero R, Garcia-Saenz JA, Guerra E, Caronia D, Casado A, Ruiz-Borrego M, Hernando B, Chacon JI, De la Torre-Montero JC, Jimeno MA, Heras L, Alonso R, De la Haba J, Pita G, Constenla M, Gonzalez-Neira A (2015) <br />Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis<br /><i>Oncologist</i> <b>20</b>: 111<br /><br />Ladero V, Herrero-Fresno A, Martinez N, Del Rio B, Linares DM, Fernandez M, Martin MC, Alvarez MA (2014) <br />Genome Sequence Analysis of the Biogenic Amine-Degrading Strain Lactobacillus casei 5b<br /><i>Genome Announc</i> <b>2</b>: <br /><br />Trapp M, Tehei M, Trovaslet M, Nachon F, Martinez N, Koza MM, Weik M, Masson P, Peters J (2014) <br />Correlation of the dynamics of native human acetylcholinesterase and its inhibited huperzine A counterpart from sub-picoseconds to nanoseconds<br /><i>J R Soc Interface</i> <b>11</b>: <br /><br />Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, Munoz-Mateu M, Caronia D, Carrasco EM, Garcia Saenz JA, Casado A, Chacon I, Hernando B, Ruiz-Borrego M, Gonzalez-Neira A (2011) <br />Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study<br /><i>J Clin Oncol</i> <b>29</b>: 1008<br /><br />